MHRA to consider evidence on transgenerational effects of sodium valproate

The regulator has asked the Commission on Human Medicines to look at data showing the transgenerational effects of sodium valproate in mice.
A mid section of a pregnant woman taking a tablet
The national valproate registry, which details the number of females prescribed valproate in England and any pregnancies among these women, was set up in June 2021

Shutterstock.com

The Medicines and Healthcare products Regulatory Agency (MHRA) is reviewing data suggesting that genetic changes triggered by sodium valproate could be passed down through generations.

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Register for free to keep on reading

Access two premium articles as a registered user.

Register

Already an RPS member or registered? Log in

Last updated